CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
| Revenue (TTM) | $60.33M |
| Gross Profit (TTM) | $52.43M |
| EBITDA | $-48.59M |
| Operating Margin | -94.30% |
| Return on Equity | -172.20% |
| Return on Assets | -31.00% |
| Revenue/Share (TTM) | $2.27 |
| Book Value | $0.48 |
| Price-to-Book | 1.96 |
| Price-to-Sales (TTM) | 0.38 |
| EV/Revenue | 0.555 |
| EV/EBITDA | -1.31 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -5.80% |
| Shares Outstanding | $26.64M |
| Float | $19.58M |
| % Insiders | 10.34% |
| % Institutions | 67.50% |
Volatility is currently contracting
CVRx, Inc. ( CVRX ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Kevin Hykes - President, CEO & Director John Landry - Chief Financial Officer Jared Oasheim - Consultant Conference Call Participants Mark Klausner - ICR Capital LLC Max Kruszeski - William Blair & Company L.L.C., Research Division Nick Mattiacci Presentation Operator Greetings.
MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following investor conferences: Canaccord Genuity Medtech, Diagnostics & Digital Health Services Forum in New York on Wednesday, Nov. 11, 2026. The fireside chat is scheduled at 8:00 a.m.
SAN FRANCISCO, Oct. 1, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer.
MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.
SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws.
Landry Brings Two Decades of Medtech and Public Company Finance Experience Landry Brings Two Decades of Medtech and Public Company Finance Experience
SAN FRANCISCO, Sept. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. ("CVRx" or the "Company") (NASDAQ: CVRX).
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
SAN FRANCISCO, Aug. 26, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights litigation firm, announces it has opened an investigation into CVRx Inc. (NASDAQ: CVRX) regarding potential violations of federal securities laws. The investigation follows disclosures of a U.S. Department of Justice Civil Investigative Demand ("CID"), severe cuts to revenue guidance, commercial sales force disruption, and the sudden termination of the company's Chief Revenue Officer.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CVRX and any ticker you trade — then tracks every position and per-strategy win rate.
